Derek J. Leishman - Concepedia

Author

Derek J. Leishman

Also Known As

DEREK J. LEISHMAN, DEREK LEISHMAN, Derek J. Leishman, Derek J Leishman, Derek J. Leishman, Derek Leishman, Leishman, Derek

139

Publications

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Pfizer (United States)Pfizer (United Kingdom)Charles River Laboratories (United States)Amgen (United States)

About

Derek J. Leishman is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	720
2	Public Health	5	5	147
3	Natural Sciences	2	2	74
4	Business	1	1	20
5	Engineering	1	1	11

Derek J. Leishman

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Structural Determinants of HERG Channel Block by Clofilium and Ibutilide Matthew Perry, Marcel J. de Groot, R. M. Helliwell, Molecular Pharmacology	2004	157
Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics Hugo M. Vargas, Alan Bass, Alexander Breidenbach, Journal of Pharmacological and Toxicological Methods Cardiovascular Translational ResearchCardiovascular DiseaseScientific ReviewCardiologyCardiovascular Toxicity	2008	124
Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Rob Webster, Derek J. Leishman, Don K. Walker PubMed PharmacotherapyExperimental PharmacologyMolecular PharmacologyTranslational MedicinePharmacological Study	2002	116
Mechanism of hERG K<sup>+</sup>channel blockade by the fluoroquinolone antibiotic moxifloxacin Ari Alexandrou, Rona S. Duncan, A SULLIVAN, British Journal of Pharmacology	2006	114
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA <i>In Silico</i> Strategy Zhihua Li, Gary R. Mirams, Takashi Yoshinaga, Clinical Pharmacology & Therapeutics	2019	106
Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 °C: Cisapride versus dofetilide James T. Milnes, Harry J. Witchel, Joanne L. Leaney, Journal of Pharmacological and Toxicological Methods	2010	96
Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs Matthew Perry, Phillip J. Stansfeld, Joanne L. Leaney, Molecular Pharmacology	2005	83
Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc David A. Price, Duncan Armour, Marcel de Groot, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyCcr5 Antagonist MaravirocMedicineHerg AffinityImmunology	2006	76
The Concordance between Nonclinical and Phase I Clinical Cardiovascular Assessment from a Cross-Company Data Sharing Initiative Lorna Ewart, Mike Aylott, Mark Deurinck, Toxicological Sciences	2014	75
Cardiac Safety Research Consortium: Can the thorough QT/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward Börje Darpö, Christine Garnett, Charles Benson, American Heart Journal Heart FailureCardiovascular Translational ResearchCardiovascular DiseasePatient SafetyCardiovascular Pharmacology	2014	61

Page 1